{"id":"W4390004386","doi":"10.1080/2162402x.2023.2290787","title":"A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Society for Immunotherapy of Cancer; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Rash; Internal medicine; Renal cell carcinoma; Oncology; Melanoma; Nausea; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Adverse effect; Cancer; Phases of clinical research; Nivolumab; Immunotherapy; Clinical trial; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002366493,0.0002233035,0.0007148343,0.0004676234,0.00005242659,0.00001538038,0.0002317968,0.00009804901,0.00002300198],"category_scores_gemma":[0.00003453267,0.0001745932,0.00002120859,0.001096647,0.0001798102,0.0002209869,0.0001039827,0.0001974544,0.000006925121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000173318,"about_ca_system_score_gemma":0.0001476765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007923762,"about_ca_topic_score_gemma":0.0009356296,"domain_scores_codex":[0.9983311,0.0001280074,0.0005202033,0.0003893232,0.0002471646,0.000384204],"domain_scores_gemma":[0.9990967,0.00005564822,0.0002469798,0.0004154146,0.0001568751,0.00002840451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07100174,0.07569356,0.7625152,0.0001557113,0.0004970232,0.0003336108,0.006728746,0.00004322335,0.0468712,0.00002179813,0.00005934128,0.03607878],"study_design_scores_gemma":[0.2496643,0.02199722,0.7225367,0.0004286047,0.00004240246,0.000007293807,0.003096535,0.0001486504,0.001766101,0.000003820307,0.0001337434,0.0001745739],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970155,0.0002217786,0.000004788697,0.0001726042,0.0001438298,0.00225551,0.000017596,0.00004358338,0.0001247502],"genre_scores_gemma":[0.9991635,0.0002020734,0.0001255366,0.00009007649,0.000004027186,0.000150403,0.0001295612,0.00003468342,0.0001001073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1786626,"threshold_uncertainty_score":0.7119706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02640003130830229,"score_gpt":0.3339655591300359,"score_spread":0.3075655278217336,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}